ASX ANNOUNCEMENT

Additional R&D Tax Incentive rebate received

Sydney, 17 February 2020. Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to announce receipt of an additional $0.65m R&D Tax Incentive rebate for the financial year 2018/2019. This brings the total R&D Tax Incentive rebate received by the Company for the 2018/2019 financial year to **$5.23m**. As previously announced, in October 2019 the Company received an initial R&D Tax Incentive rebate of $4.58m.

ENDS

Actinogen Medical
Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
@BillKetelbey

Investor and Media Enquiries
Arthur Chan
WE Communications
P: +61 2 9237 2805
E: arthurc@we-worldwide.com

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical
Actinogen Medical (ASX: ACW) is an ASX-listed biotechnology company developing novel therapies for cognitive impairment associated with chronic neurological and metabolic diseases. The company is currently developing its lead compound Xanamem as a promising new therapy for Alzheimer's disease and cognitive impairment associated with schizophrenia and mood disorders. The cognitive dysfunction associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem™
Xanamem's novel mechanism of action sets it apart from other therapies for Alzheimer's disease. It works by blocking the excess production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain, affecting memory. The 11β-HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease, schizophrenia and the mood disorders.
The Company's XanaHES Phase I trial exploring the safety and tolerability of Xanamem™ 20mg once daily in healthy elderly volunteers, showed that the drug exhibited a good safety profile with no treatment-related serious adverse events. Additionally, the trial demonstrated that Xanamem™ produced a statistically significant improvement in cognition, which, along with other data recently generated, confirms the underlying mechanism of action of Xanamem.
The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2020, including in Alzheimer's disease, and in cognitive impairment associated with schizophrenia, mood disorders and diabetes.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.